The patent-expiration dates below reflect the earliest possible expiration of a major U.S. patent, though some drugs are likely to retain exclusivity longer. Enbrel is a top seller for both Amgen ($43; NASDAQ: AMGN) and Wyeth ($43; NYSE: WYE). Amgen markets the drug in the U.S. and Canada, while Wyeth owns the marketing rights outside those two countries. Wyeth receives a portion of the profits from North American sales but does not disclose the amount.
For pipeline drugs, we considered only those with expected launch dates of 2011 or sooner. In addition, we did not include any direct extensions of existing product lines. All revenue projections represent consensus analyst estimates of total drug sales, though some companies must share revenue with partners. 2007 sales exclude revenue from medical devices and supplies, consumer products, animal pharmaceuticals, and health services, if companies provide a breakdown.